Evidence map›Paper›PMID 38378929›Full record

ReviewArchives of virology2024

Antiviral alternatives against important members of the subfamily Parvovirinae: a review.

Tamiris Silva Lopes, Vagner Ricardo Lunge, André Felipe Streck

Erratum issuedAbstract readReview
PubMed Publisher
In one paragraph

Review in Archives of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tamiris Silva LopesUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
Vagner Ricardo LungeUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil.
André Felipe StreckUniversidade de Caxias do Sul, Caxias do Sul, RS, Brazil. afstreck@ucs.br.ORCID http://orcid.org/0000-0002-4798-0777
Universidade de Caxias do Sul · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico Conselho Nacional de Desenvolvimento Científico e Tecnológico
6 · The paper itself

Abstract

Parvoviruses are responsible for multiple diseases, and there is a critical need for effective antiviral therapies. Specific antiviral treatments for parvovirus infections are currently lacking, and the available options are mostly supportive and symptomatic. In recent years, significant research efforts have been directed toward understanding the molecular mechanisms of parvovirus replication and identifying potential targets for antiviral interventions. This review highlights the structure, pathogenesis, and treatment options for major viruses of the subfamily Parvovirinae, such as parvovirus B19 (B19V), canine parvovirus type 2 (CPV-2), and porcine parvovirus (PPV) and also describes different approaches in the development of antiviral alternatives against parvovirus, including drug repurposing, serendipity, and computational tools (molecular docking and artificial intelligence) in drug discovery. These advances greatly increase the likelihood of discoveries that will lead to potent antiviral strategies against different parvovirus infections.

Indexed as

Parvoviridae InfectionsParvovirinaeParvovirusParvovirus B19, HumanAnimalsAntiviral AgentsArtificial IntelligenceMolecular Docking SimulationSwineAntiviral Agentscanine parvovirusparvovirus B19pathogenesisporcine parvovirusTreatments

Identifiers

PMID38378929
OpenAlexW4391971196

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.